Conflict-of-interest by clinical investigators
This article was originally published in The Tan Sheet
Executive Summary
Will be the subject of a Sept. 9 meeting of FDA's Science Advisory Board at the request of FDA Commissioner David Kessler. The agency is currently working on a notice of proposed rulemaking on financial disclosure of clinical trial investigators that is slated for publication this fall. The science advisory board meeting will be held at the Ramada Inn in Bethesda, Md. beginning at 8:00 a.m. . . .
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning